Table 2.
Tumor response
| C→E | E→C | p-value | |
|---|---|---|---|
| Best overall response to CDK4/6 inhibitor-based regimen | Measurable (n=37) | Measurable (n=32) | |
| Partial response | 18 (48.6) | 7 (21.9) | |
| Stable disease | 15 (40.5) | 13 (40.6) | |
| Progressive disease | 4 (10.8) | 11 (34.4) | |
| Not evaluated | 0 | 1 (3.1)a) | |
| Best overall response to EVE-based regimen | Measurable (n=44) | Measurable (n=30) | |
| Partial response | 4 (9.1) | 6 (20.0) | |
| Stable disease | 28 (63.6) | 20 (66.7) | |
| Progressive disease | 10 (22.7) | 4 (13.3) | |
| Not evaluated | 2 (4.5) | 0 | |
| Overall response rate b) | |||
| Overall response rate to EVE | 4/42 (9.5) | 6/30 (20.0) | 0.302 |
| Overall response rate to CDK4/6 inhibitor | 18/37 (48.6) | 7/31 (22.6) | 0.049 |
Values are presented as number (%). C or CDK4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor; E or EVE, everolimus.
a)
Not evaluated due to the loss of follow-up,
b)
Including patients with measurable disease, and had at least one tumor response evaluation result. All best objective responses for objective response rate were partial responses.